NTRA stock news today

Natera awarded $19.3 million in patent case against ArcherDX

A jury sided with Natera in its patent infringement dispute with ArcherDX, awarding the company $19.3 million. The verdict resolves one legal claim between the two testing firms.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

MyOme and SickKids team up on genetic tests that read methylation marks

MyOme and SickKids will work together so that methylation signatures become part of genetic testing. The two organizations announced the collaboration but gave no financial terms.

Natera says three peer-reviewed papers cover its Signatera test in head and neck tumors

Natera reported that three new peer-reviewed papers address use of its Signatera assay for tumors of the head and neck. The company said the studies add to the evidence behind the test.

Natera's Signatera MRD test gains Medicare coverage for hepatocellular carcinoma

Natera said its Signatera molecular residual disease test now has Medicare coverage for hepatocellular carcinoma. The decision expands reimbursement for the test to patients with this type of liver cancer.

Natera finance chief Michael Burkes Brophy offloads stock

The chief financial officer of Natera, Michael Burkes Brophy, has sold company stock, per a disclosure. The filing details the executive's share disposal.

Chief executive of Natera offloads stock valued at $2.38 million

The top executive at Natera, Steven Leonard Chapman, disposed of company shares totaling $2.38 million. A filing shows the transaction.

BTIG Keeps Buy Rating on Natera, Lifts Price Target to $430

BTIG reiterated its Buy rating on Natera and raised its price target to $430. The change reflects the firm's updated view on the stock.

Natera Reports Bladder Cancer Findings for Signatera at ESMO 2026

Natera presented new results for its Signatera test at a 2026 medical meeting. The findings link ctDNA changes to survival outcomes in people with bladder cancer.

BTIG kept its Buy rating on Natera (NTRA) with a price target of $430.

Natera co-founder and director Jonathan Sheena sells company shares

Jonathan Sheena, a co-founder and director at Natera, sold shares of the company. The headline gives no details on the size, price or timing of the sale.

Natera presents findings at ASN Kidney Week 2026

Natera shared study results during the ASN Kidney Week 2026 event. The company presented analyses based on patient care experience.

Roth Capital Partners starts Natera coverage with Buy rating

Roth Capital Partners began covering Natera, Inc. and assigned a Buy rating to the stock. The rating reflects the firm's view on the company's shares.

Roth MKM Starts Natera Coverage With Buy Rating

Roth MKM began covering Natera and assigned a Buy rating to the stock. The initiation is an analyst action on the company.

Roth Capital started coverage of Natera (NTRA) with a Buy rating and a price target of $475.

Natera Insider Sells Shares Valued at $603,710

An insider at Natera sold company stock worth $603,710. Insider sales can reflect personal financial decisions and do not necessarily indicate a change in the company's prospects.

Matthew Rabinowitz, Natera's Executive Chairman, Offloads 50,000 Shares

A filing shows the executive chairman of Natera, Matthew Rabinowitz, disposed of 50,000 shares. No price, date or rationale for the transaction was included.

Canaccord keeps Buy on Natera, lifts target to $500 from $375

Canaccord Genuity reiterated its Buy rating on Natera and increased its price target to $500 from $375. The stock moved higher following the analyst update.

Canaccord Genuity keeps Buy rating on Natera, lifts price target

Canaccord Genuity reiterated its Buy rating on Natera and increased its price target on the shares. The change reflects the firm's updated view on the stock.

Canaccord Genuity keeps Buy rating on Natera, lifts target to $500

Canaccord Genuity reiterated its Buy rating on Natera and raised its price target to $500. The move reflects the firm's updated view on the stock.

Canaccord Genuity raised its price target on Natera (NTRA) to $500 from $375.

Natera to Report SAGITTARIUS Trial Results at ESMO 2026

Natera plans to present late-stage study findings at ESMO 2026. Signatera results led to changed care for a third of colon cancer patients, and 87% of those reduced treatment after testing negative for residual disease.

Morgan Stanley keeps Overweight rating on Natera, lifts target to $435

Morgan Stanley reiterated its Overweight rating on Natera and raised its price target to $435. The update reflects the firm's latest view on the stock.

TD Cowen keeps Buy rating on Natera, lifts target to $480

TD Cowen reiterated its Buy rating on Natera and raised its price target to $480. The change reflects the firm's updated view on the stock.

Natera Posts Second-Quarter 2026 Financials, Hosts Call

Natera has released its financial figures for the second quarter of 2026 and held an earnings call, a full transcript of which is available.

Natera's multi-cancer early detection assay gets FDA breakthrough device designation

Natera's multi-cancer early detection assay has been granted breakthrough device designation by the FDA. The status is meant to speed up review of devices that could offer major advantages over existing options.

What is the latest news on NTRA?

Nov 4, 2026: Natera awarded $19.3 million in patent case against ArcherDX (Fiscal.ai) · Nov 4, 2026: Natera, Inc. filed an insider trading report (Form 4) (SEC) · Nov 4, 2026: MyOme and SickKids team up on genetic tests that read methylation marks (Fiscal.ai)

What are analysts saying about NTRA?

Oct 27, 2026: BTIG kept its Buy rating on Natera (NTRA) with a price target of $430. · Oct 22, 2026: Roth Capital started coverage of Natera (NTRA) with a Buy rating and a price target of $475. · Oct 19, 2026: Canaccord Genuity raised its price target on Natera (NTRA) to $500 from $375.

What has NTRA filed with the SEC recently?

Nov 4, 2026: Natera, Inc. filed an insider trading report (Form 4)